This is a match-making section for JPIAMR 14th call - Disrupting drug Resistance Using Innovative Design (DRUID).
Human Health
in silico, in vitro, in vivo
Tuberculosis AMR Host pathogen interaction Mode of actions HTS High Content assays
Our lab expertise is on monitoring Intracellular growth of Mycobacteria inside infected macrophages, cell lines and primary cells with and without drugs. Identification of drug targets and mode of action of novel compounds either within the bug or within the host-pathogen interaction. We have a state of the art BCL-3 facility capable of working with AMR and clinical isolates of Mycobacterium tuberculosis and NTMs.
Development of novel compounds targeting XDR and MDR TB. Repurposing drugs for TB and NTM. Synergy studies in an in vitro and ex vivo assays. Hit to Lead projects.
Submitted on 2022-01-26 09:28:36
« Return to the partner search tool